Cart
sales@molnova.com
p38α inhibitor 1
CAS No. 1034189-82-6
p38α inhibitor 1( P38alpha inhibitor 1 | ARRY-797 | P38a inhibitor 1 )
Catalog No. M26356 CAS No. 1034189-82-6
p38α inhibitor 1 is an inhibitor of p38α .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 45 | In Stock |
|
| 2MG | 29 | In Stock |
|
| 5MG | 42 | In Stock |
|
| 10MG | 67 | In Stock |
|
| 25MG | 136 | In Stock |
|
| 50MG | 197 | In Stock |
|
| 100MG | 276 | In Stock |
|
| 200MG | 368 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namep38α inhibitor 1
-
NoteResearch use only, not for human use.
-
Brief Descriptionp38α inhibitor 1 is an inhibitor of p38α .
-
Descriptionp38α inhibitor 1 is an inhibitor of p38α .
-
In Vitro——
-
In Vivo——
-
SynonymsP38alpha inhibitor 1 | ARRY-797 | P38a inhibitor 1
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1034189-82-6
-
Formula Weight416.473
-
Molecular FormulaC22H26F2N4O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 125 mg/mL (300.15 mM)
-
SMILESCC(C)Cn1ncc2cc(Oc3ccc(F)cc3F)c(cc12)C(=O)NCCN(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Moncrieff M, Fadhil M, Garioch J. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases (LIMMs) of the skin. The 5-Year Norwich experience. Br J Dermatol. 2015 Nov 24.
molnova catalog
related products
-
PF-03715455
PF-03715455 is a highly potent and selective inhibitor for p38α MAPK with IC50 of 1.6 nM.
-
AMG-548
AMG-548 is a potent and selective inhibitor of p38α with Ki of 0.5 nM, dispalys weak inhibition for p38β (Ki=3.6 nM), and >5,000-fold selectivity over p38γ and p38δ.
-
Antimicrobial agent-...
Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment of cataracts, ulcerative colitis, meningitis and Kawasaki's disease and Parkinson's disease.
